- Published at
- by manilatimes.net
mixed
mixed
News for Acumen Pharmaceuticals, Inc. (ABOS)
- Published at
- by gurufocus.com
positivepositiveAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. ( ABOS) (”Acumen” or the ”Company”), a clinical-stage biopharmaceutical- Published at
- by gurufocus.com
positivepositiveAcumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration supports furthe- Published at
- by gurufocus.com
positivepositiveAcumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals ( ABOS) CEO Danie- Published at
- by gurufocus.com
positivepositiveAcumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTI- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
neutralneutralHalozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
PR NewswireSAN DIEGO, Feb. 26, 2025 SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that D- Published at
- by gurufocus.com
mixedmixedHALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
PR NewswireSAN DIEGO, Feb. 18, 2025 Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 millionFou- Published at
- by gurufocus.com
mixedmixedCHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
PR NewswireSAN DIEGO, Feb. 3, 2025 SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janss- Published at
- by investing.com
positivepositiveAcumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102- Published at
- by investing.com
positivepositiveAcumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 By Investing.com
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692- Published at
- by investing.com
positivepositiveAcumen Pharmaceuticals chief legal officer sells shares worth $5,434 By Investing.com
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434- Published at
- by gurufocus.com
positivepositiveAcumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early- Published at
- by investing.com
positivepositiveAcumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com
Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock- Published at
- by investing.com
positivepositiveAcumen Pharmaceuticals COO Barton Russell sells $14,225 in stock By Investing.com
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock- Published at
- by gurufocus.com
neutralneutralHalozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
PR NewswireSAN DIEGO, Dec. 30, 2024 SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Tak- Published at
- by investing.com
mixedmixedHalozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE ® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo ® (nivolumab) Indications By Investin
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE ® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo ® (nivolumab) Indications- Published at
- by gurufocus.com
mixedmixedHalozyme to Present at Upcoming Investor Conferences
PR NewswireSAN DIEGO, Nov. 27, 2024 SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that m- Published at
- by investing.com
mixedmixedHALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS By Investing.com
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS- Published at
- by investing.com
mixedmixed4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation
Stocks Analysis by Ismael De La Cruz covering: Blink Charging Co, Eledon Pharmaceuticals Inc, Nio Inc Class A ADR, Acumen Pharmaceuticals Inc. Read Ismael De La Cruz's latest article on Investing.com